iShares U.S. Healthcare ETF (NYSEARCA:IYH) Reaches New 1-Year High – Time to Buy?

iShares U.S. Healthcare ETF (NYSEARCA:IYH)’s stock price reached a new 52-week high during mid-day trading on Thursday. The company traded as high as $74.76 and last traded at $74.9590, with a volume of 9,399 shares. The stock had previously closed at $73.16.

iShares U.S. Healthcare ETF Stock Performance

The firm has a market capitalization of $4.34 billion, a PE ratio of 21.05 and a beta of 0.56. The company has a fifty day moving average price of $71.71 and a 200-day moving average price of $66.82.

Institutional Investors Weigh In On iShares U.S. Healthcare ETF

A number of hedge funds have recently bought and sold shares of IYH. Mather Group LLC. bought a new stake in iShares U.S. Healthcare ETF in the 3rd quarter worth approximately $33,000. First Citizens Bank & Trust Co. purchased a new stake in shares of iShares U.S. Healthcare ETF in the third quarter worth about $657,000. Forvis Mazars Wealth Advisors LLC purchased a new position in iShares U.S. Healthcare ETF in the third quarter worth about $394,000. Sax Wealth Advisors LLC boosted its holdings in iShares U.S. Healthcare ETF by 4.7% during the 3rd quarter. Sax Wealth Advisors LLC now owns 6,804 shares of the company’s stock valued at $487,000 after acquiring an additional 307 shares during the period. Finally, Atlas Brown Inc. bought a new position in iShares U.S. Healthcare ETF during the 3rd quarter worth about $268,000.

iShares U.S. Healthcare ETF Company Profile

iShares U.S. Healthcare ETF (the Fund), formerly iShares Dow Jones U.S. Healthcare Sector Index Fund (the Fund) is a non-diversified exchange-traded fund. The Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Dow Jones U.S. Health Care Index (the Index). The Index measures the performance of the healthcare sector of the United States equity market, and includes companies in the industry groups, such as healthcare equipment and services, pharmaceuticals and biotechnology.